Treating Negative Symptoms in Schizophrenia: an Update
Open accessThe DOI matches its Crossref record; 123 of the 123 references it cites were found in a registry or an index.
Abstract
Interest in the negative symptoms of schizophrenia has increased rapidly over the last several decades, paralleling a growing interest in functional, in addition to clinical, recovery, and evidence underscoring the importance negative symptoms play in the former. Efforts continue to better define and measure negative symptoms, distinguish their impact from that of other symptom domains, and establish effective treatments as well as trials to assess these. Multiple interventions have been the subject of investigation, to date, including numerous pharmacological strategies, brain stimulation, and non-somatic approaches. Level and quality of evidence vary considerably, but to this point, no specific treatment can be recommended. This is particularly problematic for individuals burdened with negative symptoms in the face of mild or absent positive symptoms. Presently, clinicians will sometimes turn to interventions that are seen as more "benign" and in line with routine clinical practice. Strategies include use of atypical antipsychotics, ensuring the lowest possible antipsychotic dose that maintains control of positive symptoms (this can involve a shift from antipsychotic polypharmacy to monotherapy), possibly an antidepressant trial (given diagnostic uncertainty and the frequent use of these drugs in schizophrenia), and non-somatic interventions (e.g., cognitive behavioral therapy, CBT). The array and diversity of strategies currently under investigation highlight the lack of evidence-based treatments and our limited understanding regarding negative symptoms underlying etiology and pathophysiology. Their onset, which can precede the first psychotic break, also means that treatments are delayed. From this perspective, identification of biomarkers and/or endophenotypes permitting earlier diagnosis and intervention may serve to improve treatment efficacy as well as outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular pathology of schizophrenia: more than one disease process?
Crow, T. J. (1980) · BMJ · doi:10.1136/bmj.280.6207.66 · Cited by 1,856 · cited 1×
“As a result, it was postulated that these features would not be amenable to pharmacotherapy in the same fashion as positive symptoms [12].”
BackgroundDeficit and nondeficit forms of schizophrenia: the concept
(1988) · American Journal of Psychiatry · doi:10.1176/ajp.145.5.578 · Cited by 1,332 · cited 1×
“, deficit) and secondary negative symptoms [3], although clinically”
BackgroundThe NIMH-MATRICS Consensus Statement on Negative Symptoms
Kirkpatrick, B., Fenton, W. S., Carpenter, W. T., & Marder, S. R. (2006) · Schizophrenia Bulletin · doi:10.1093/schbul/sbj053 · Cited by 1,311 · cited 2×
“between primary and secondary negative symptoms is not essential [4].”
BackgroundFusar-Poli, P., Papanastasiou, E., Stahl, D., Rocchetti, M., Carpenter, W., Shergill, S., & McGuire, P. (2015) · Schizophrenia Bulletin · doi:10.1093/schbul/sbu170 · Cited by 683
A Separate Disease Within the Syndrome of Schizophrenia
Kirkpatrick, B., Buchanan, R. W., Ross, D. E., & Carpenter, W. T. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.2.165 · Cited by 651 · cited 1×
“To this last point, work focusing on the prodrome of schizophrenia indicates that deficit symptoms and cognitive impairment are evident by the time of the first psychotic break [8, 9], while enduring primary negative symptoms have been identified in approximately 25–30 % of individuals with chronic schizophrenia [10].”
BackgroundProvocative tests with psychostimulant drugs in schizophrenia
Lieberman, J. A., Kane, J. M., & Alvir, J. (1987) · Psychopharmacology · doi:10.1007/bf00216006 · Cited by 532
The role of inflammation in schizophrenia
Müller, N., Weidinger, E., Leitner, B., & Schwarz, M. J. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00372 · Cited by 465
Millan, M. J., Fone, K., Steckler, T., & Horan, W. P. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.03.008 · Cited by 347
Bora, E., Lin, A., Wood, S. J., Yung, A. R., McGorry, P. D., & Pantelis, C. (2014) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12261 · Cited by 294 · cited 1×
“To this last point, work focusing on the prodrome of schizophrenia indicates that deficit symptoms and cognitive impairment are evident by the time of the first psychotic break [8, 9], while enduring primary negative symptoms have been identified in approximately 25–30 % of individuals with chronic schizophrenia [10].”
BackgroundNegative symptoms in individuals at clinical high risk of psychosis
Piskulic, D., Addington, J., Cadenhead, K. S., Cannon, T. D., Cornblatt, B. A., Heinssen, R., Perkins, D. O., Seidman, L. J., Tsuang, M. T., Walker, E. F., et al. (2012) · Psychiatry Research · doi:10.1016/j.psychres.2012.02.018 · Cited by 282 · cited 1×
“To this last point, work focusing on the prodrome of schizophrenia indicates that deficit symptoms and cognitive impairment are evident by the time of the first psychotic break [8, 9], while enduring primary negative symptoms have been identified in approximately 25–30 % of individuals with chronic schizophrenia [10].”
Background
Cited by
Ferguson, B. R., & Gao, W.-J. (2018) · Frontiers in Neural Circuits · doi:10.3389/fncir.2018.00037 · Cited by 594
Cerebellar-Prefrontal Network Connectivity and Negative Symptoms in Schizophrenia
Brady, R. O., Gonsalvez, I., Lee, I., Öngür, D., Seidman, L. J., Schmahmann, J. D., Eack, S. M., Keshavan, M. S., Pascual-Leone, A., & Halko, M. A. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.18040429 · Cited by 372
“The development of new interventions for these negative symptoms is hampered by a critical shortfall in our understanding of their pathophysiology, and our ability to modify the functional impact of schizophrenia is further limited by the fact that psychotropic medications have limited efficacy in treating negative sy…”
Predictive processing, source monitoring, and psychosis
Griffin, J. D., & Fletcher, P. C. (2017) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-032816-045145 · Cited by 133
Adery, L. H., Ichinose, M., Torregrossa, L. J., Wade, J., Nichols, H., Bekele, E., Bian, D., Gizdic, A., Granholm, E., Sarkar, N., et al. (2018) · Psychiatry Research · doi:10.1016/j.psychres.2018.10.014 · Cited by 80
Böge, K., Hahne, I., Bergmann, N., Wingenfeld, K., Zierhut, M., Thomas, N., Ta, T. M. T., Bajbouj, M., & Hahn, E. (2021) · Schizophrenia Research · doi:10.1016/j.schres.2020.12.008 · Cited by 44
Liu, Y., Li, I., & Hsiao, F. (2021) · Journal of Advanced Nursing · doi:10.1111/jan.14750 · Cited by 41
Butcher, I., Berry, K., & Haddock, G. (2020) · British Journal of Clinical Psychology · doi:10.1111/bjc.12248 · Cited by 29
“In terms of treatment, there has been a particular surge in research in the last 20 years (Remington et al., 2016; Stahl & Buckley, 2007).”
Background
Metadata
- Authors
- Remington, G., Foussias, G., Fervaha, G., Agid, O., Takeuchi, H., Lee, J., & Hahn, M.
- Venue
- Current Treatment Options in Psychiatry
- Published
- 2016-04-08
- Volume
- 3
- Issue
- 2
- Pages
- 133-150
- ISSN
- 2196-3061 (ISSN-L)
- OpenAlex
- W2318201734
- Cited by
- 167
- References
- 123
- FWCI
- 14.23
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.